CellSource Co

CellSource Co OCF/Debt

The Operating Cash Flow to Debt Ratio of CellSource Co (4880.T) as of Nov 20, 2026 is 587.27 %. In the previous year, Operating Cash Flow to Debt Ratio was 765.59 % — a change of -23.29% (lower).

OCF/Debt

587.27 %

YoY

-23.29%

Last updated:

Operating Cash Flow to Debt Ratio of CellSource Co is 2025 587.27 % . Operating Cash Flow to Debt Ratio of CellSource Co was 2024 765.59 % . It decreases by -23.29% lower compared to the previous year.

The CellSource Co OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
2,666.40 JPY
Jan 1, 2020
7,706.53 JPY
Jan 1, 2021
81,877.30 JPY
Jan 1, 2023
868.03 JPY
Jan 1, 2024
765.59 JPY
Jan 1, 2025
587.27 JPY
The CellSource Co OCF/Debt history
YEAROCF/DebtYoY
587.27 %-23.29%
765.59 %-11.80%
868.03 %-98.94%
81,877.30 %+962.44%
7,706.53 %+189.02%
2,666.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSource Co Stock analysis

What does CellSource Co do? CellSource Co., Ltd. generates revenue through its Regenerative Medicine Related business segment, which provides contracted services for processing tissues and cells from fat and blood to medical institutions, along with support services for regenerative medicine laws and regulations related to safety assurance. The company also sells medical equipment within this segment. The Consumer business segment focuses on selling cosmetics and facial products directly to general consumers. Both segments operate under the company's brand without additional brand names mentioned in the description. The Regenerative Medicine Related business segment targets medical institutions and regulatory compliance support for regenerative medicine safety, while the Consumer business segment serves general consumers seeking cosmetics and facial care products. The company's products include processed tissue and cell services, regulatory support, medical equipment, and consumer skincare items, all sold under the CellSource brand. CellSource Co., Ltd. employs 109 full-time employees to manage its two business segments, with the Regenerative Medicine Related segment handling medical services and equipment sales, and the Consumer segment focusing on direct-to-consumer product sales. The company's revenue streams are derived from these two distinct operational areas without any additional external partnerships or third-party brands. CellSource Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSource Co stock

Operating Cash Flow to Debt Ratio of CellSource Co is 587.27 % in 2025.

Operating Cash Flow to Debt Ratio of CellSource Co changed from 765.59 % to 587.27 %, representing a -23.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio CellSource Co since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's CellSource Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — CellSource Co

All Key Metrics — CellSource Co